BioGend Therapeutics Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 21.06 million compared to TWD 9.57 million a year ago. Net loss was TWD 42.37 million compared to TWD 52.04 million a year ago. Basic loss per share from continuing operations was TWD 0.36 compared to TWD 0.5 a year ago. Diluted loss per share from continuing operations was TWD 0.36 compared to TWD 0.5 a year ago.
For the nine months, sales was TWD 70.34 million compared to TWD 20.45 million a year ago. Net loss was TWD 123.62 million compared to TWD 131.14 million a year ago. Basic loss per share from continuing operations was TWD 1.04 compared to TWD 1.27 a year ago. Diluted loss per share from continuing operations was TWD 1.04 compared to TWD 1.27 a year ago.